The global antibody drug conjugates market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028. The Antibody Drug Conjugates (ADCs) market is a rapidly evolving sector within the biopharmaceutical industry, characterized by its innovative approach to targeted cancer therapy. ADCs combine...